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ABSTRACT 52 
Glioblastoma is the most frequent malignant primary brain tumor. In a hierarchical 53 
tumor model, glioblastoma stem-like cells (GSC) play a major role in tumor initiation 54 
and maintenance as well as in therapy resistance and recurrence. Thus, targeting 55 
this cellular subset may be key to effective immunotherapy. Here, we present a mass 56 
spectrometry-based analysis of HLA-presented peptidomes of GSC and glioblastoma 57 
patient specimens. Based on the analysis of patient samples (n=9) and GSC (n=3) 58 
we performed comparative HLA peptidome profiling against a dataset of normal 59 
human tissues. Using this immunopeptidome-centric approach we could clearly 60 
delineate a subset of naturally presented, GSC-associated HLA ligands, which might 61 
serve as highly specific targets for T cell-based immunotherapy. In total, we identified 62 
17 antigens represented by 41 different HLA ligands showing natural and exclusive 63 
presentation both on GSC and patient samples. Importantly, in vitro immunogenicity 64 
and antigen-specific target cell killing assays suggest these peptides to be epitopes 65 
of functional CD8+ T cell responses, thus rendering them prime candidates for 66 
antigen-specific immunotherapy of glioblastoma. 67 
68 
 5 
INTRODUCTION 69 
Glioblastoma, the most frequent malignant primary brain tumor, carries a poor 70 
prognosis despite advances in surgery, radiation- and chemotherapy [37]. This 71 
dilemma calls for innovative approaches, one of the most promising of which is T 72 
cell-based immunotherapy. The impressive clinical efficacy of immune checkpoint 73 
inhibitors in a subset of patients with extracranial malignancies demonstrates the 74 
potential of T cell-based immunotherapy to induce and maintain long-lasting anti-75 
tumor immune responses [4,29,10]. Since the clinical benefit of immune checkpoint 76 
inhibition is associated with high numbers of tumor-associated somatic mutations and 77 
since this mutational burden is rather low in glioblastoma [1], T cell epitopes from 78 
non-mutated sources may represent the most actionable targets in glioblastoma. 79 
Such targets may be utilized to boost or direct the specificities of anti-tumoral T cell 80 
responses e.g. by combination therapies of checkpoint blockade and peptide 81 
vaccination or in adoptive cellular approaches. In this context, the identification of 82 
appropriate targets is crucial. A central challenge in targeting a highly heterogeneous 83 
tumor such as glioblastoma is to prevent positive clonal selection of antigen loss 84 
variants [19].  85 
In recent years, there is growing evidence for the presence of glioma-initiating cells 86 
exhibiting stem cell properties, which can be designated as glioblastoma stem-like 87 
cells (GSC) [9,27]. In a hierarchical tumor model, GSC are supposed to have 88 
important functions in the initiation, maintenance, and therapy resistance of 89 
glioblastoma and therefore warrant evaluation as a possible target for 90 
immunotherapy. 91 
By mapping the HLA peptidome of glioblastoma and GSC, we identified a new panel 92 
of T cell antigens characterized by exclusive detection on malignant specimens, a 93 
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high frequency of presentation as well as representation on the glioblastoma stem 94 
cell compartment. This study is based on the in-depth HLA peptidome analysis of 3 95 
established GSC lines (GS-2, GS-5, GS-9), which have been characterized 96 
extensively for stable stemness properties [9,40], as well as 9 freshly resected 97 
glioblastoma samples. This glioblastoma cohort was analyzed in relation to a 98 
comprehensive dataset of HLA ligands presented on various normal human tissues 99 
including normal human brain. In contrast to previous studies on the HLA peptidome 100 
of glioblastoma [7] [20] our extensive dataset allows for a purely HLA peptidome-101 
centric analysis of the antigenic landscape of bulk patient tumors and the 102 
glioblastoma stem cell compartment as represented by GSC. Notably, cluster and 103 
network analyses revealed direct evidence for the gliogenesis and stem cell fate 104 
determination being reflected in the intersection of patient tumor and GSC 105 
immunopeptidomes. Furthermore, in vitro priming assays demonstrated the induction 106 
of specific T cell responses for a subset of these novel target candidates, 107 
underscoring their potential for T cell immunotherapy.  108 
 109 
 110 
 111 
 112 
 113 
 114 
 115 
 116 
 117 
 118 
 119 
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MATERIALS AND METHODS 120 
Patients and blood samples. Primary tissue of patients with histologically confirmed 121 
glioblastoma who underwent surgery at the Department of Neurosurgery at the 122 
University Hospital Zurich was immediately snap-frozen in liquid nitrogen during 123 
surgery and stored at –80 °C. Written informed consent was obtained from each 124 
glioblastoma patient as well as from patients and healthy donors that contributed to 125 
the normal tissue database in accordance with the local ethical requirements and the 126 
Declaration of Helsinki. Institutions that contributed samples to the normal tissue 127 
database are listed in the Supplementary Methods (Online Resource 1). 128 
Peripheral blood mononuclear cells (PBMC) of healthy donors for functional 129 
experiments were isolated by density gradient centrifugation. HLA typing of cell lines 130 
and tumor samples was carried out at the Department of Hematology and Oncology, 131 
University of Tübingen, Germany. PBMC of HLA-typed healthy donors were provided 132 
by the Department of Transfusion Medicine, University of Tübingen, Germany and by 133 
the Swiss Red Cross Blood Transfusion Services Zurich and Chur, Switzerland. 134 
All analyses were performed according to the guidelines of the local ethics 135 
committees (KEK-ZH-Nr. 2015-0163). 136 
 137 
Cell lines and GSC culture expansion. We used established GSC lines GS-2, GS-138 
5, GS-9, which have been characterized extensively for stable stemness properties 139 
[40,9]. GSC were provided by the Department of Neurosurgery at the University 140 
Hospital Hamburg-Eppendorf. Cells were tested for mycoplasma contamination every 141 
3 months using a PCR-based test kit. Cell line authentication and exclusion of cross-142 
contamination was performed showing stable HLA typing (PCR with sequence-143 
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specific primers) from original cell lines and cell pellets used for experiments. GSC 144 
were thawed around passages 15-20 and before using the cells for experiments they 145 
were passaged 6-8 times. GSC were maintained in neurobasal medium with B-27 146 
supplement (20 µl/ml) and glutamax (10 µl/ml) (all Invitrogen, Karlsruhe, Germany), 147 
as well as ﬁbroblast growth factor (FGF)-2, epidermal growth factor (EGF) (20 ng/ml 148 
each; Peprotech, Rocky Hill, PA, USA) and heparin (32 IE/ml; Ratiopharm, Ulm, 149 
Germany). Stem cell factors were supplemented twice a week, the medium was 150 
changed once a week. Cells were passaged when spheres reached an estimated 151 
diameter of 500 μm or an estimated density of 5 x 104 cells/cm2. Spheres were 152 
dissociated mechanically and enzymatically (accutase; PAA, Vienna, Austria). After 153 
culture expansion, GSC line cell pellets (1 ml each) were harvested and snap-frozen. 154 
Three experimental replicates per GSC line were produced and each experimental 155 
replicate was used for the isolation of HLA ligands with subsequent analysis by LC-156 
MS/MS in 5 technical replicates (as described below). 157 
 158 
Immunofluorescence. Five x 105 cells were cytospun onto a glass slide, dried for 30 159 
min and fixed in 4% formaldehyde for 10 min. Subsequently, the cells were stained 160 
using mouse monoclonal primary antibody to HLA-A, -B, -C (EMR8-5; 1:50; BD 161 
Pharmingen, Franklin Lakes, NJ, USA) or the mouse monoclonal primary antibody to 162 
HLA class II (ab55152; 1:50; Abcam, Cambridge, UK) followed by permeabilization 163 
with 0.5% Triton X100 and incubation with goat anti-rabbit IgG-Alexa Fluor 488-164 
coupled secondary antibody (Invitrogen) (diluted 1:100) and nuclear DNA labeling 165 
with DAPI (Invitrogen) for visualization. Images were acquired using a Leica SP5 166 
confocal microscope (Leica Microsystems, Wetzlar, Germany). 167 
 168 
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Immunohistochemistry. Immunohistochemistry was carried out on cytospins 169 
(prepared as described above) or paraformaldehyde-fixed paraffin-embedded glioma 170 
sections. Cytospins or sections were stained using the mouse monoclonal primary 171 
antibody to HLA-A, -B, -C (1:50) (BD Pharmingen) or the mouse monoclonal primary 172 
antibody to HLA class II (1:50) (Abcam) and visualized using anti-mouse secondary 173 
antibody with ImmPACT DAB kit (Vector, Burlingame, CA, USA). Binding specificity 174 
was controlled by an isotype control. Images were acquired using a Zeiss Scope.A1 175 
microscope (Carl Zeiss Microscopy, Jena, Germany). 176 
 177 
Isolation of HLA ligands. HLA class I molecules were isolated using standard 178 
immunoaffinity purification [16,8]. In brief, snap-frozen GSC pellets or snap-frozen 179 
primary glioblastoma tissue samples were lysed in 10 mM CHAPS/PBS (AppliChem, 180 
St. Louis, MO, USA/Gibco, Carlsbad, CA, USA) containing 1x protease inhibitor 181 
(Complete; Roche, Basel, Switzerland). HLA molecules were single-step purified 182 
using the pan-HLA class I-specific mAb W6/32 (produced in-house) covalently linked 183 
to CNBr-activated sepharose (GE Healthcare, Chalfont St Giles, UK). For the 184 
immunoprecipitation of HLA class II-peptide complexes, we used equal amounts of 185 
the HLA-DR-specific antibody L243 as well as the pan-HLA class II-specific antibody 186 
Tü39 (both produced in-house). A mixture of HLA-DR specific L243 and pan-class II 187 
specific Tü39 was used to isolate class II peptide-HLA complexes. HLA-DR1 is 188 
known to be expressed at higher levels than the other class II allotypes, therefore the 189 
specific L243 mAb at the given stoichiometry was used. Tü39 is utilized 190 
complementarily to pull-down the remaining class II complexes. HLA–peptide 191 
complexes were eluted by repeated addition of 0.2% TFA (trifluoroacetic acid, Merck, 192 
Whitehouse Station, NJ, USA). Eluted HLA ligands were purified by ultrafiltration 193 
using centrifugal filter units (Amicon; Millipore, Billerica, MA, USA). HLA ligands were 194 
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desalted using ZipTip C18 pipette tips (Millipore). Extracted peptides were eluted in 195 
35 μl 80% acetonitrile (Merck)/0.2% TFA, centrifuged to complete dryness and 196 
resuspended in 25 μl of 1% acetonitrile/0.05% TFA. Samples were stored at −20°C 197 
until analysis by LC-MS/MS. 198 
 199 
Analysis of HLA ligands by LC-MS/MS. Peptide samples were separated by 200 
reversed-phase liquid chromatography (nano-UHPLC, UltiMate 3000 RSLCnano; 201 
Thermo Fisher, Waltham, MA, USA) and analyzed in online-coupled LTQ Orbitrap XL 202 
or Orbitrap Fusion Lumos mass spectrometers (both Thermo Fisher). Samples were 203 
analyzed in five (Orbitrap XL) or three (Fusion Lumos) technical replicates. Sample 204 
shares of 20% (Orbitrap XL) or 10% (Fusion Lumos) were trapped on a 75 μm x 2 cm 205 
trapping column (Acclaim PepMap RSLC; Thermo Fisher) at 4 μl/min for 5.75 min. 206 
Peptide separation was performed at 50°C and a flow rate of 175 nl/min on a 50 μm x 207 
25 cm separation column (Acclaim PepMap RSLC; Thermo Fisher) applying a 208 
gradient ranging from 2.4 to 32.0% of acetonitrile over the course of 90 min. The 209 
majority of samples were analyzed on an LTQ Orbitrap XL using a top five CID 210 
(collision-induced dissociation) method with survey scans at 60k resolution and 211 
fragment ion detection in the ion trap (ITMS2) operated at normal scan speed. Seven 212 
normal tissue specimens from the central nervous system (brain04 – brain07 and 213 
cerebellum04, cerebellum06, cerebellum07) were analyzed on the Orbitrap Fusion 214 
Lumos for tumor-exclusivity validation of targets implementing a top speed CID 215 
method with survey scans at 120k resolution and fragment detection in the Orbitrap 216 
(OTMS2) at 60k resolution. On both instruments, the mass range was limited to 400–217 
650 m/z with precursors of charge states 2+ and 3+ eligible for fragmentation. For 218 
HLA class II, a mass range of 300–1,500 m/z was analyzed with charge states ≥2 219 
selected for fragmentation. 220 
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Database search and spectral annotation. The software Proteome Discoverer 221 
(v.1.3; Thermo Fisher) was used to perform database search using the Mascot 222 
search engine (Mascot 2.2.04; Matrix Science, London, UK) for ITMS2 data and 223 
Sequest (ThermoFisher) for OTMS2 data. The human proteome as comprised in the 224 
Swiss-Prot database (http: //www.uniprot.org, status September 2013, 20,225 225 
reviewed sequences contained) was used as reference database. The search 226 
combined data of technical replicates and was not restricted by enzymatic specificity. 227 
Precursor mass tolerance was set to 5 ppm, and fragment mass tolerance to 0.5 Da 228 
for ITMS2 data and 0.02 Da for OTMS2 data, respectively. Oxidation of methionine 229 
residues was allowed as a dynamic modification. False discovery rate (FDR) was 230 
estimated using the Percolator node [14] and was limited to 5%. ITMS2 peptide IDs 231 
were further filtered for Mascot Ion scores ⩾20. For HLA class I ligands, peptide 232 
lengths were limited to 8–12 amino acids (AA), for HLA class II, peptides were limited 233 
to 12–25 AA of length. Protein grouping was disabled, allowing for multiple 234 
annotations of peptides, e.g. for conserved sequences mapping into multiple 235 
proteins. As a final step of quality control, thresholds of ⩾ 500 (HLA class I, primary 236 
glioblastoma tissue), ⩾200 (HLA class I, GSC), unique ligand identifications per 237 
sample were applied. HLA annotation was performed using the prediction tool 238 
SYFPEITHI (http: //www.syfpeithi.de) or an extended in-house database [22]. 239 
Experimental validation of the predicted HLA restriction was obtained by peptide 240 
synthesis and functional characterization for a subset of ligands. 241 
 242 
Peptide synthesis. Synthetic peptides for the validation of mass spectrometric 243 
identifications as well as for functional experiments were synthesized using the 244 
automated peptide synthesizer EPS221 (Abimed, Langenfeld, Germany) and the 9-245 
fluorenylmethyloxycarbonyl/tert-butyl (Fmoc/tBu) strategy [28]. 246 
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CD8+ T cell priming using aAPC. Priming of CD8+ T cells was performed using 247 
artificial antigen presenting cells (aAPC) according to a standard protocol [35]. PBMC 248 
were isolated from fresh buffy coats of healthy volunteers using standard density 249 
gradient centrifugation. CD8+ T cells were MACS-enriched by positive selection 250 
(Miltenyi Biotec, Bergisch Gladbach, Germany). 251 
In vitro stimulations were initiated in 24-well plates with 5 x 106 responder cells plus 252 
106 beads per well in 1.5 ml of T cell medium consisting of RPMI 1640 containing 25 253 
mM HEPES (Life Technologies/Invitrogen) supplemented with 10% heat-inactivated 254 
human AB serum (CC Pro, Neustadt/Weinstraße, Germany), 2 mM L-glutamine, 50 255 
U/ml penicillin, 50 μg/ml streptomycin, and 20 μg/ml gentamicin (all 256 
BioWhittaker/Cambrex, Verviers, Belgium). Five ng/ml human IL-12 p70 (R&D 257 
Systems) was added with aAPC. After 4 days of co-incubation at 37°C, fresh medium 258 
and 20 U/ml human IL-2 (R&D Systems) were added, and cells were incubated for 3 259 
days. This stimulation cycle was repeated twice and tetramer staining was performed 260 
on day 21. 261 
 262 
Intracellular cytokine and tetramer staining. The frequency and functionality of 263 
peptide-specific CD8+ T cells was analyzed by intracellular IFN-γ and TNF-α staining 264 
as described previously [21,39]. PBMC were pulsed with 10 μg/ml of individual 265 
peptide and incubated in the presence of 10 μg/ml Brefeldin A (Sigma Aldrich) and 266 
10 μg/ml GolgiStop (BD Biosciences) for 6–8 h. Cells were labeled using 267 
Cytofix/Cytoperm (BD Biosciences), CD8-PECy7 (Beckman Coulter, Fullerton, CA, 268 
USA), CD4-APC (BD Biosciences), TNFα-PE (Beckman Coulter), and IFNγ-FITC 269 
(BD Biosciences). Samples were analyzed on a FACS Canto II (BD, Franklin Lakes, 270 
NJ, USA). The frequency of peptide-specific CD8+ T cells was determined by 271 
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staining with anti-CD8 and HLA:peptide-tetramer-PE [25]. Cultures were considered 272 
positive when >1% of tetramer-positive cells among CD8+ cells were detected.  273 
 274 
Cytotoxicity assay. Tetramer-positive cells were enriched by FACS cell sorting (BD 275 
FACSAria III, BD Biosciences) and subsequent expansion using irradiated PBMC as 276 
feeder cells and 3000 U/ml IL-2 (PeproTech, London, UK) and 30 ng/ml OKT3 277 
(eBioscience, Thermo Fisher). Medium supplemented with IL-2 and OKT3 was 278 
changed twice a week. Tetramer-negative cells were expanded in parallel as 279 
controls. T cell-mediated GSC lysis was determined using a flow cytometry-based 280 
cytotoxicity assay. A single cell suspension of target cells was stained with PKH-26 281 
(Sigma-Aldrich, St. Louis, MO, USA) for 3 min and then co-incubated with T effector 282 
cells at different effector to target (E:T) ratios as indicated for 20 h. Subsequently, 283 
live/dead staining was performed with Zombie NIR Fixable Viability Kit (BioLegend, 284 
San Diego, CA, USA) followed by assessment of target cell lysis by flow cytometry. 285 
Specific cell lysis was expressed as percentage of dead cells within the PKH-26-286 
positive target cells, corrected for spontaneous background lysis. 287 
 288 
Software, statistical analysis and online tools. Flow cytometric data analysis was 289 
performed using FlowJo 7.2 (Tree Star Inc., Ashland, OR, USA). In-house R scripts 290 
(https://www.r-project.org) were used for the calculation of TAA false discovery rates 291 
and unsupervised hierarchical clustering of HLA ligand source proteins. Overlap 292 
analyses were done using VENNY (Oliveros, J.C. (2007-2015) Venny. An interactive 293 
tool for comparing lists with Venn's diagrams 294 
(http://bioinfogp.cnb.csic.es/tools/venny/index.html) as well as the online tool 295 
BioVenn [13]. Functional Annotation charts were created using DAVID (https://david-296 
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d.ncifcrf.gov) [12,11]. The network analysis of GSC and patient specific source 297 
proteins was performed using GeneMania (http://www.genemania.org; default 298 
settings) [36]. Bar charts were created using Microsoft Excel 2015 (Redmond, WA, 299 
USA), box plots and line graphs were done using Prism 5 (GraphPad Software, San 300 
Diego, CA). Kaplan–Meier analysis of survival probability and gene expression 301 
analysis for the Glioma–French–284–MAS5.0–u133p2 dataset (n=284, glioblastoma 302 
n=156) in the database of The Cancer Genome Atlas (TCGA) 303 
(http://cancergenome.nih.gov) was done using glioblastoma database entries only 304 
(n=156) and using the R2 microarray analysis and visualization platform 305 
(http://r2.amc.nl) using a cut off for high expression (top 25%) versus the rest. 306 
Survival was analyzed separately for glioblastoma patients regardless of IDH1 307 
mutation status (n=156) and for patients with known IDH1 mutation status harboring 308 
no IDH1 mutation (IDH1 wt, n=92). 309 
 310 
RESULTS 311 
Mapping the antigenic landscape of naturally presented HLA class I and II 312 
ligands on primary glioblastoma and GSC. As a prerequisite for HLA ligandome 313 
profiling we analyzed HLA class I and class II expression on GSC (Fig 1a,b) and 314 
patient samples (Fig. 1c), showing robust membrane staining for both GSC and 315 
patient samples. The workflow of our antigen discovery approach is summarized in 316 
Fig. 2a-b. Three different GSC lines (GS-2, GS-5, GS-9) were culture-expanded and 317 
cell pellets (1 ml each) as well as 9 freshly resected glioblastoma samples were 318 
snap-frozen. Tumor samples and three experimental replicates per GSC line were 319 
used for the isolation of HLA ligands with subsequent analysis by LC-MS/MS in 5 320 
technical replicates. HLA ligandome mapping was done in comparison with an 321 
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extensive HLA peptidome database. For HLA class I, this database comprised 160 322 
different human normal tissues including central nervous system samples (n=13) with 323 
a total of 46,429 peptides derived from 12,245 source proteins. A list of normal 324 
tissues included in this database is provided in Supplementary Table 1 (Online 325 
Resource 2). Comparative profiling of HLA ligand source proteins from tumor 326 
samples and benign tissue samples was performed separately for HLA class I and II 327 
based on the frequency of HLA-restricted representation (Fig. 2c). The overlap 328 
between GSC, patient samples and normal tissues is depicted in Fig. 2d-g for both, 329 
source protein and HLA ligand level. HLA class I peptidome analysis of the GSC 330 
lines and patient samples yielded a total of 9,770 peptide identifications, representing 331 
5,703 source proteins. Mapping of the HLA class II ligandome identified 2,942 332 
different peptides derived from 1,121 distinct source proteins. Basic patient 333 
characteristics including HLA typing and peptide yields are provided in Table 1. The 3 334 
cell lines and 9 patient samples included a total of 23 different HLA-A and -B 335 
allotypes; 99.3% of individuals of the Caucasian population have at least one HLA-A 336 
or -B allotype that is represented by this tumor dataset (calculated by the IEDB 337 
population coverage tool www.iedb.org). The most frequent allotypes were HLA-A*02 338 
(n=7), -A*03 (n=6), -B*44 (n=5), and -B*18 (n=3). The HLA allotype-dependent 339 
population coverage is depicted in Supplementary Fig. 1 (Online Resource 3). 340 
Peptide yields per sample and the length distribution of peptides are shown in Fig. 341 
3a-b. A list of all peptides and corresponding source proteins from tumor samples 342 
and normal tissue is provided in Supplementary Table 2 (Online Resource 4). 343 
 344 
 345 
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Gene ontology and network analysis shows enrichment for stem cell- and 346 
development-associated functions of GSC-associated glioblastoma antigens. 347 
Functional annotation based on gene ontology (GO) terms revealed distinct cellular 348 
compartments for HLA ligand source proteins presented on HLA class I compared to 349 
HLA class II (Supplementary Table 3 (Online Resource 5)). The most frequent 350 
compartment identifiers were „cytoplasm“ for HLA class I and „extracellular/exosome“ 351 
for HLA class II. Interestingly, plasma membrane components were overrepresented 352 
in HLA class I tumor-exclusive source proteins. In line with that finding, GO term 353 
analysis for „biological process” detected „homophilic cell adhesion molecules“ to be 354 
enriched in HLA class I and II tumor-exclusive source proteins (Supplementary Table 355 
4 (Online Resource 6), hinting at an important role for membrane proteins as a 356 
source for glioblastoma-specific HLA ligands. Molecular function GO annotation did 357 
not reveal any major differences between the two HLA classes (Supplementary Table 358 
5 (Online Resource 7)). Notably, network analysis of the 44 class I antigens shared 359 
by GSC and patient samples showed involvement of stem cell- and development-360 
related functions (Fig. 2h, Supplementary Table 6 (Online Resource 8)) with 361 
„gliogenesis“ and „stem cell development“ among the two top-ranking terms.  362 
 363 
HLA class I ligand source proteins from GSC cluster with patient-derived 364 
tumors, but both are distinct from normal brain samples. Regarding GSC, a total 365 
of 4,863 peptides derived from 3,698 different source proteins were identified. The 366 
overlap of HLA class I source proteins and peptide ligands of the 3 GSC lines is 367 
depicted in Fig. 3c. As expected, the overlap was much smaller on the HLA 368 
peptidome level compared to the source protein level, mainly due to expression of 369 
different HLA allotypes between cell lines. Regarding primary patient samples, a total 370 
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of 6,459 peptides representing 4,198 source proteins were identified. Unsupervised 371 
hierarchical clustering of HLA ligand source proteins represented on GSC, patient 372 
samples or normal brain specimens delineated a distinct cluster for normal brain 373 
specimens, which was well separated from the mixed cluster of primary glioblastoma 374 
and GSC samples (Fig. 3d). Notably, normal brain specimens showed a considerable 375 
degree of inter-sample homogeneity with a broad set of common antigens 376 
represented in their HLA peptidomes. In contrast, primary glioblastoma and GSC 377 
lines showed high levels of inter-patient/tumor heterogeneity with large blocks of 378 
unique antigens represented in their HLA peptidomes indicative of unique tumor 379 
biology and/or disruptive effects of malignant transformation on HLA-restricted 380 
antigen presentation. Nevertheless, sets of tumor-associated common antigens were 381 
identified leading to the distinct clustering of patient tumors and GSC samples. The 382 
similarity of individual GSC and patient samples based on the calculation of the 383 
Jaccard coefficient is depicted in Supplementary Figure 2 (Online Resource 9). The 384 
underlying raw data of the clustering is provided in Supplementary Table 7 (Online 385 
Resource 10). 386 
Comparative profiling of HLA class I peptidomes of primary samples and GSC 387 
versus normal tissues identifies a subset of GSC-associated glioblastoma 388 
antigens. When compared to normal tissues, 224 source proteins were exclusively 389 
represented in the HLA peptidome of GSC, 44 proteins were commonly represented 390 
on both GSC and solid glioblastoma, and 219 source proteins were specific for 391 
primary bulk glioblastoma (Fig 2e). The FDR of antigen discovery at different 392 
thresholds of tumor-exclusive frequency were estimated based on dataset 393 
randomization and are shown for HLA class I in Fig. 4a. Aiming for an antigen-394 
discovery specific FDR of <5%, antigens were required to be exclusively presented 395 
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on at least 3 of 12 (25%) malignant samples leading to an estimated FDR of 3.15% 396 
for the identified tumor antigens. Using the criteria of (i) tumor-exclusive 397 
representation on the HLA peptidome level, (ii) common representation on both GSC 398 
and primary patient samples, and (iii) a frequency of at least 3/12 malignant samples 399 
to yield <5% false-positive antigen discovery, we identified 14 HLA class I antigens 400 
represented by 28 HLA ligands (Supplementary Table 8 (Online Resource 11)). 401 
Peptides mapping into multiple proteins that do not fulfill these criteria were excluded. 402 
Based on microarray data from TCGA, these candidates are expressed in both 403 
glioblastoma samples (Fig. 4c) and normal brain tissue (Supplementary Fig. 3 404 
(Online Resource 12)). However, differential gene expression was deliberately not a 405 
criterion of this antigen discovery approach. As a rough estimate for the relative 406 
abundance of candidate peptides within each sample we plotted the precursor 407 
intensity distributions and highlighted candidate peptides in red for GSC (Fig. 4d-f) 408 
and for primary patient specimens (Supplementary Fig. 4 (Online Resource 13)), 409 
revealing a broad range of presentation levels for these candidate targets. Kaplan-410 
Meier survival analysis of candidates based on TCGA data revealed prolonged 411 
survival in a cohort of glioblastoma patients with high expression of RTFN2. The 412 
same analysis in this cohort considering only patients with known IDH1 mutation 413 
status and IDH1 wild-type tumors did not show a significant survival difference. No 414 
survival effects were observed for the other candidates (Supplementary Fig. 5 415 
(Online Resource 14)). 416 
A minority of HLA class I ligands derived from cancer testis antigens is tumor-417 
exclusive and most of the tumor-exclusive CTA-derived ligands are presented 418 
on GSC. Cancer testis genes code for a group of immunogenic proteins (CTA, 419 
cancer testis antigens) expressed in theory almost exclusively in germ cells located 420 
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in immunoprivileged sites, but notably also in various human cancer types. This 421 
expression pattern led to CTA being considered prime targets for antigen-specific 422 
immunotherapy and CTA are targets of ongoing clinical trials in glioblastoma (e.g. 423 
NCT02546102 or NCT02208362; www.clinicaltrials.gov). Overlap analysis of 424 
established CTA (as comprised in CTDatabase; http://www.cta.lncc.br/) and tumor-425 
exclusive source proteins from GSC and patient samples revealed the presentation 426 
of 6 CTA represented by 6 corresponding peptides, shown in Fig. 5a-b. The majority 427 
of proteins listed in the CTDatabase (133/206; 65%) was neither represented in the 428 
HLA ligandome of normal tissues nor on tumor samples. A total of 23/206 (11%) 429 
proteins were represented in the HLA ligandome overlap between malignant and 430 
benign tissue, 44/206 (21%) were exclusively represented on normal tissues and 431 
only a minority of CTA was tumor-exclusive (6/206; 3%). Interestingly, 4/6 (67%) CTA 432 
were only identified on GSC although GSC made up only 3/12 (25%) of the samples, 433 
indicating aberrant expression or HLA-restricted presentation of these targets 434 
selectively on glioblastoma stem cells. Regarding survival analysis, no effects were 435 
seen for high expression of the CTA except for an unfavorable prognosis of high 436 
interleukin-13 receptor subunit alpha-2 (IL13RA2) expression, which was not the 437 
case in the subgroup of IDH1 wild-type tumors (Supplementary Fig. 5 (Online 438 
Resource 14)). 439 
 440 
Mapping the HLA class II ligandome of glioblastoma and GSC extends the 441 
options for synergistic immunotherapy. Although the numbers of peptide 442 
identifications were lower than on HLA class I, class II peptidome analysis resulted in 443 
the identification of 1,321 peptides representing 623 source proteins from GSC as 444 
well as in 1,877 peptides representing 814 source proteins derived from patient 445 
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samples. Comparative HLA peptidome analysis revealed 137 source proteins and 446 
1,260 corresponding peptides to be identified exclusively on malignant samples and 447 
6 source proteins (represented by 26 peptides) to be shared between GSC and 448 
patient samples (Fig. 2f-g). For HLA class II antigen discovery, the FDR threshold 449 
was set to a frequency of presentation on at least 3/12 malignant samples resulting in 450 
an estimated FDR of 3.33% (Fig. 4b). Three out of 6 tumor-exclusive proteins shared 451 
between GSC and patient samples (SERPINE1, FABP7, PTGFRN) represented by 452 
13 HLA-bound peptides passed this threshold (Supplementary Table 8 (Online 453 
Resource 11)). Comparing HLA class I and class II peptidomes, we identified 765 454 
dually represented source proteins, 12 of which were tumor-exclusive (Fig. 3e). We 455 
found 263 HLA class I peptide sequences that were embedded within longer HLA 456 
class II peptides. Notably, of these, 59 overlapped with HLA class I tumor-exclusive 457 
peptide sequences pointing toward an attractive option for synergistic 458 
immunotherapy. No differences in survival was seen for the three HLA class II 459 
candidate antigens (Supplementary Fig. 5 (Online Resource 14)). 460 
Functional characterization of GSC-associated HLA class I peptides reveals 461 
specific immune recognition, degranulation and antigen-specific cytotoxicity of 462 
T cells. The top 3 (based on frequency) shared glioblastoma/GSC peptides (all A*02-463 
restricted) ALFPERITV (ATAT1), RLAPFVYLL (HEPACAM), and SILDIVTKV 464 
(RFTN2) as well as 2 CTA-derived peptides LLDTNYNLFY (IL13R2; A*01-465 
restricted) and FVYGEPREL (MAGEC2; A*02-restriced) were synthesized and 466 
subjected to immunological characterization. Peptide-specific immunogenicity was 467 
verified by priming of naïve T cells from healthy donors followed by HLA multimer 468 
staining (Fig. 6a). In addition, for ATAT1 and RFTN2 T cells were functionally 469 
characterized after priming by intracellular cytokine staining (ICS) detecting the 470 
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induction of the master pro-inflammatory cytokines interferon gamma (IFNγ), tumor 471 
necrosis factor alpha (TNFα) and the degranulation marker CD107a (Fig. 6b). 472 
Supplementary Table 9 (Online Resource 15) summarizes the T cell priming results. 473 
Antigen-specific cytotoxicity of T cells after sorting of tetramer-positive CD8+ T cells 474 
and subsequent expansion was shown for ALFPERITV (ATAT1), RLAPFVYLL 475 
(HEPACAM), and SILDIVTKV (RFTN2) (Fig. 6c). Gene expression in GSC was 476 
shown for these three candidates. However, RNA-mediated gene silencing did not 477 
show a consistent effect on the GSC phenotype regarding proliferation, migration, 478 
and self-renewal (Supplementary Fig. 6 (Online Resource 16), Supplementary 479 
Methods (Online Resource 1)). 480 
 481 
 482 
DISCUSSION  483 
By (i) mapping the natural immunopeptidome of the glioblastoma stem cell 484 
compartment, (ii) a first description of the HLA class II ligandome in glioblastoma (iii) 485 
the definition of a novel subset of GSC-associated antigens in glioblastoma, which 486 
were defined based on direct evidence on the immunologically pivotal level of HLA-487 
restricted antigen presentation, rather than based on gene expression and/or in silico 488 
predictions, our study may help guiding the informed design of immunotherapeutic 489 
interventions targeting the glioblastoma stem cell compartment. 490 
Notably, the potential of targeting HLA class II-restricted antigens was recently 491 
underscored by clinical data on the crucial role of HLA class II and CD4+ T cells in 492 
immunological tumor rejection [17,26,30]. Furthermore, detailed knowledge on 493 
natural HLA class II antigen presentation patterns will allow for tailoring multi-epitope 494 
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peptide vaccines containing both HLA class I- and HLA class II-restricted targets, 495 
which may induce and boost synergistic CD8+ and CD4+ anti-tumor responses. 496 
A major focus of this study was the comparative analysis of the ligandome of GSC 497 
and patient samples with the aim of identifying GSC-associated targets also present 498 
on primary patient tumors. Bearing in mind that GSC are culture expanded ex vivo 499 
and therefore subject to potential cell culture artefact, we performed a comparative 500 
side-by-side analysis of GSC and patient samples. Freshly resected glioblastoma 501 
patient samples represent the natural state of the HLA peptidome of glioblastoma as 502 
present in vivo. However, freshly resected patient samples are contaminated by non-503 
tumorous cells (i.e. endothelium, microglia, infiltrating leukocytes and leukocytes from 504 
blood contamination). In contrast, GSC are composed of tumor cells only, thus 505 
tumor-exclusive patient sample-derived ligands that can also be found on GSC are 506 
unlikely to be derived from non-tumorous cells. Vice versa, GSC-derived HLA ligands 507 
that can also be found in freshly resected patient samples are unlikely to be an 508 
artefact of cell culture. In addition, hierarchical clustering analysis of HLA class I 509 
peptidomes clearly delineated normal brain samples as a distinct cluster whereas 510 
GSC were determined to be more similar to patient samples. Another advantage of 511 
focusing on the overlap between GSC and primary patient samples is the potential 512 
similarity between GSC and adult stem cells. As GSC and normal neuroglial stem 513 
cells might share common properties [38], a high acuity of separation between these 514 
two is needed in order to prevent collateral damage to the physiological stem cell 515 
pool. Together, this strongly suggests antigens identified by our strategy represent 516 
naturally presented and highly specific targets for the immunotherapy of the 517 
glioblastoma stem cell compartment. 518 
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Recently, an antigen discovery approach for GSC-associated T cell targets was 519 
presented by Rapp and colleagues, which is based on proteomics and subsequent 520 
immunogenicity testing [23]. Peptides used for immunogenicity assays were based 521 
on in silico predictions. Albeit the abundance and turnover of source proteins has 522 
been shown to globally correlate with HLA class I-restricted peptide presentation [3], 523 
there is still a high degree of variability in sampling for HLA-restricted presentation for 524 
individual proteins, which warrants the direct analysis of HLA peptidomes for antigen 525 
discovery. Therefore, we strictly relied on HLA peptidome level analyses to identify 526 
targets by comparative HLA ligandome profiling of GSC and patient samples in 527 
relation to a comprehensive database of various human normal tissues including 528 
human brain. Both approaches complement each other and add important targets for 529 
immunotherapy of glioblastoma including the GSC compartment. 530 
Regarding HLA ligands derived from CTA it is worth noting that 4/6 (67%) of CTA 531 
were solely identified on GSC, although GSC only contribute 3/12 (25%) of the 532 
samples. We hypothesize that this over-representation of CTA on GSC might be due 533 
to a shift towards germ-line gene expression patterns and an undifferentiated 534 
phenotype of GSC, which is consistent with the findings of our network analysis. This 535 
is in line with previous findings of enhanced CTA expression in GSC [42]. 536 
Interestingly, the 3,686 HLA-A*02-restricted peptides identified on freshly resected 537 
glioblastoma in a previous study by Dutoit et al. [7] did not include previously 538 
reported HLA-A*02-restricted glioblastoma peptides from EGFRvIII, Eph-2A, gp100, 539 
HER2, IL-13Rα2, MAGEA1, TRP-2, SOX-2, -3, -11 and WT1 [6]. Dutoit et al. 540 
identified peptides derived from EGFR and Eph-A2 other than the previously 541 
published ones. We found peptides derived from MAGEA1, SOX-2, SOX-11 und IL-542 
13Rα2, which all were detected on GSC and never on patient samples. In addition, 543 
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all peptides derived from these source proteins were restricted to HLA allotypes other 544 
than HLA-A*02. This could further highlight the importance of analyzing GSC as a 545 
source of suitable antigens and also underscores the importance of mapping non-546 
HLA-A*02 peptidomes for antigen discovery. Of note, the HLA-A*01-restricted 547 
peptide LLDTNYNLFY is derived from the source protein IL13R2. Recently, a report 548 
of glioblastoma tumor regression after intracranial infusion of IL13R2-targeted 549 
chimeric antigen receptor (CAR) T cells was published [5], which supports the utility 550 
of IL13R2 as a potential target for immunotherapy.  551 
The increasing availability of next generation sequencing was accompanied by a 552 
shifting focus towards mutation-derived neoepitopes. These neoantigens are, in 553 
theory, tumor-specific and immunogenic and recent studies showed promising 554 
clinical results in malignancies other than glioblastoma [24,30,32]. Our approach is 555 
not designed or able to detect neoantigens as all mass spectrometry data acquired in 556 
this study was uniformly processed against a reference proteome. However, this 557 
enables us to sensitively detect non-mutated antigens derived from „self”, which are 558 
well established in tumor-immunology [31,34] and recently have been shown to be 559 
targets of pathophysiologically relevant anti-cancer immune responses in leukemia 560 
patients [15]. Compared to other malignancies, the number of somatic mutations in 561 
glioblastoma is rather low [1]. Even in tumors with a high mutational burden, peptides 562 
derived from mutated sequences are exceedingly rare [41]. In general, the number of 563 
mutated tumor antigens that elicit frequent and effective anti-tumor immune 564 
responses appears to be quite small even in the setting of checkpoint inhibition 565 
[2,18]. A reason for the low prevalence of neoantigens even in tumors with high 566 
mutational burden might be a clonal selection of neoantigen loss variants by 567 
immunoediting [33].  568 
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A limitation of this study is the low number of normal brain tissues and the variation of 569 
HLA allotypes on the normal tissue side. In theory, target candidates may lose their 570 
tumor exclusivity by future expansion of the normal issue database. However, the 571 
potential utility of candidate targets from our comparative approach is strengthened 572 
by the evidence of antigen-specific T cell populations in functional assays. Overall, 573 
the HLA-centric antigen discovery approach implemented in our study highlights a 574 
strategy to broaden the repertoire of targetable antigens by adding a novel class of 575 
GSC-associated antigens, which – upon further target validation – may be utilized in 576 
both patient-individualized and off-the-shelf approaches.  577 
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FIGURE LEGENDS 734 
 735 
Fig. 1 HLA class I and II molecules are expressed on GS cells and patient samples. 736 
a-b GS-2, GS-5 and GS-9 cells were analyzed for HLA class I and II cell surface 737 
levels by immunocytochemistry (a) or immunofluorescence (b) and nuclei were 738 
counterstained with hematoxylin or DAPI, respectively (scale bar, 50 µm). c HLA 739 
class I and II protein levels were assessed on glioblastoma specimens by 740 
immunohistochemistry and nuclei were counterstained with hematoxylin (scale bar, 741 
50 µm for 20x or 40x magnification) 742 
 743 
Fig. 2 Experimental workflow and overview of HLA ligandome mapping results. a 744 
Snap-frozen GSC pellets or snap-frozen glioblastoma patient samples were lysed 745 
and HLA molecules were single-step immunopurified using the pan-HLA class I-746 
specific mAb W6/32 covalently linked to CNBr-activated sepharose. For HLA class II, 747 
we used equal amounts of the HLA-DR-specific antibody L243 as well as the pan-748 
HLA class II-specific antibody Tü39. Eluted HLA peptide ligands were purified by 749 
ultrafiltration, desalted and subjected to analysis by LC-MS/MS. b Candidate 750 
peptides for immunotherapy were defined by tumor exclusivity, shared presentation 751 
on both GSC and patient samples and a sufficient frequency on tumor samples in 752 
order to pass false discovery rate criteria for antigens. Peptides mapping into multiple 753 
proteins that do not fulfill these criteria were excluded. Candidates fulfilling the criteria 754 
mentioned above underwent functional immunogenicity testing. c Comparative 755 
profiling of HLA class I and class II ligand source proteins based on the frequency of 756 
HLA-restricted representation in malignant tissues (red bars, GSC and patient 757 
samples) versus normal tissues (blue bars). Frequencies [%] for HLA-restricted 758 
presentation of the respective source protein (x axis) are indicated on the y axis for 759 
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tumor-derived samples and normal controls separately. d-g VENN diagrams 760 
depicting the overlap between GSC, glioblastoma patient samples and an HLA 761 
ligandome normal tissue database (including normal brain) on source protein level for 762 
HLA class I (e) and HLA class II (g) as well as on peptide level (HLA class I (d); HLA 763 
class II (f)). The red circle in (e) depicts the 50 proteins, on which the network 764 
diagram shown in (h) is based on. h GeneMANIA network analysis of HLA class I-765 
presented tumor-exclusive source proteins derived from the overlap of GSC and 766 
patient samples (n=50). Nodes of involved tumor-exclusive source proteins (n=50) 767 
are striped (grey), nodes of supplemented genes for network analysis are completely 768 
filled. Edges represent physical interactions (red), co-expression (violet), genetic 769 
interactions (green), shared protein domains (yellow) and co-localization (blue). 770 
Selected enriched functions are depicted as colored pie charts of nodes. All enriched 771 
pathways are listed in Supplementary Table 6 (Online Resource 8) 772 
 773 
Fig. 3 Characterization of HLA ligands a Peptide yields per sample are shown for 774 
HLA class I (blue bars) and HLA class II (red bars). b Length distribution of HLA 775 
class I (blue bars) peptides and HLA class II (red bars) peptides c VENN diagrams 776 
depicting the overlap between the 3 GSC lines (GS-2, GS-5, GS-9) on source protein 777 
level as well as on peptide level for HLA class I and HLA class II. d Unsupervised 778 
heatmap analysis of core dataset samples that were acquired with the Orbitrap XL 779 
mass spectrometer based on source proteins represented by HLA ligands of GSC 780 
(yellow; n=3), patient samples (red; n=9) and normal brain samples (green; brain 781 
(n=2), cerebellum (n=2), amygdalahippocampectomy (AHE, n=1)). Hierachical 782 
clustering is based on qualitative data and color coding is based on semi-quantitative 783 
data (area of precursor ions). Only unique protein IDs (proteins represented by 784 
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peptides, which match to a single source protein) represented by peptides with 785 
predicted HLA binding (NetMHC 3.4 percentile rank < 2%) for at least one of the 786 
HLA-A and –B allotypes expressed by the sample were included. The number of 787 
protein entries is determined by the size of the smallest sample (Cerebellum-02; 788 
n=135). e The overlap between HLA class I and HLA class II regarding all tumor 789 
source proteins (GSC and patient samples combined) as well as the overlap of 790 
tumor-exclusive proteins is depicted. In addition, HLA class I ligand sequences that 791 
were embedded in HLA class II sequences were compared to HLA class I tumor-792 
exclusive peptide sequences  793 
 794 
Fig. 4 Characterization of candidate antigens. a-b Statistical analysis of the likelihood 795 
of false positive tumor-associated antigen (TAA) identifications at different 796 
representation frequencies for HLA class I TAA (a) and HLA class II TAA (b). The 797 
numbers of original TAA identified based on the analysis of GSC and patient samples 798 
were compared with random virtual TAA. Virtual samples were generated in silico 799 
based on random weighted sampling from the entirety of protein identifications in 800 
both original cohorts. Virtual ligandomes were generated using a defined size of the 801 
mean number of protein identifications in all analyzed samples. The process of 802 
protein randomization, cohort assembly and TAA identification was repeated 1,000 803 
times and the mean value of resulting virtual TAAs was calculated and plotted for the 804 
different threshold values. Experimental and virtual TAA are shown as bars and 805 
corresponding false discovery rates for any chosen TAA threshold are shown as a 806 
line diagram. c TCGA microarray data were used to screen for gene expression of 807 
candidate antigens. d-e The intensity rank of candidates within the precursor area 808 
distribution in GSC samples is shown for d GS-2, e GS-5, and f GS-9. The area 809 
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under the curve (AUC) of the MS1 precursor ion of a given peptide is used as semi-810 
quantitative marker for peptide abundance 811 
Fig. 5 HLA ligandome representation of cancer testis antigens. a Overlap between 812 
CTA according to the CTDatabase (http://www.cta.lncc.br), tumor source proteins 813 
and normal tissue source proteins. b 7 peptides derived from 6 CTA that were 814 
exclusively presented on tumor samples 815 
 816 
Fig. 6 T cell priming of top-ranking candidates. Immunogenicity of TAA-derived 817 
peptides was assessed by priming of CD8+ T cells with artificial antigen-presenting 818 
cells (aAPC; polystyrene beads coated with HLA/peptide complex monomers and 819 
anti-CD28 antibodies). T cell responses were detected by staining with 820 
phycoerythrin-labelled HLA-peptide multimer complexes and a response was 821 
considered positive when >1% of tetramer-positive cells among CD8+ cells were 822 
observed. a HLA-peptide multimer+ populations following priming are shown for 823 
SILDIVKTV compared to a negative control (HIV peptide). b FACS-based 824 
intracellular cytokine staining of CD8+ T cells after in vitro priming. Following re-825 
stimulation with the peptide SILDIVKTV (RFTN2), T cells produce the pro-826 
inflammatory cytokines interferon gamma (IFNγ) and tumor necrosis factor alpha 827 
(TNFα) as well as the degranulation marker CD107a. YLLPAIHVI (RNA helicase p68) 828 
was used as a negative control. c Tetramer-positive cells were enriched by flow 829 
cytometry-based cell sorting and subsequent expansion. Tetramer-negative cells 830 
were expanded in parallel as controls. Expanded T cells were used as effectors in a 831 
20 h cell lysis assay with GS-9 target cells, peptide-pulsed (1 µM) or unpulsed, at 832 
various effector : target (E:T) ratios as indicated. The percentage of target cell lysis 833 
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corrected for spontaneous background lysis is shown (++, p < 0.001, relative to 834 
corresponding unpulsed tetramer-negative T cells; *, < 0.05, relative to pulsed 835 
tetramer-negative T cells; **, < 0.01, relative to pulsed tetramer-negative T cells) 836 
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Table 1 Basic patient characteristics, HLA types, IDH1 status, and peptide yields of GSC lines and glioblastoma patient samples. 
sample/cell line sex age [years] histological 
diagnosis 
HLA-typing IDH1 status HLA class I 
peptides 
(PSM) 
source 
proteins 
HLA class 
II peptides 
(PSM) 
source 
proteins 
GS-2 (cell line) M 57 glioblastoma 
(second 
recurrence) 
A*01, A*02, 
B*15, B*57 
IDH1 wt 2,089 
(46,410) 
1,869 
 
739    
(8,519) 
425 
GS-5 (cell line) M 85 primary 
glioblastoma 
A*02, A*03, 
B*18, B*35 
IDH1 wt 1,621 
(21,852) 
1,503 
 
514   
(3,182) 
248 
GS-9 (cell line) M 69 primary 
glioblastoma 
A*02, A*25, 
B*18, B*44 
IDH1 wt 1,551 
(27,287) 
1,638 
 
375   
(2,423) 
273 
 
ZH-442 (patient 
sample) 
M 58 primary 
glioblastoma 
A*02, A*03, 
B*44, B*57 
IDH1 wt 1,111 
(9,684) 
 
1,107 
 
313  
(2,532) 
 
138 
 
ZH-443 (patient 
sample) 
F 71 primary 
glioblastoma 
A*02, A*03, 
B*07, B*45 
IDH1 wt 1,625 
(10,309) 
1,473 
 
344 
(2,353) 
 
234 
 
ZH-446 (patient 
sample) 
F 47 primary 
glioblastoma 
A*02, A*25, 
B*08, B*18 
IDH1 wt 557 
(5,971) 
614 
 
104 
(1,247) 
141 
 
ZH-450 (patient 
sample) 
M 9 primary 
glioblastoma 
A*03, A*26, 
B*08, B*27 
IDH1 wt 512 
(6,268) 
579 
 
120 
(1,451) 
164 
ZH-457 (patient 
sample) 
F 58 primary 
gliosarcoma 
A*03, A*29, 
B*13, B*44 
IDH1 wt 1,067 
(10,272) 
 
1,067 
 
417 
(3,115) 
 
215 
 
table 1 Click here to download table R3 Table 1 .docx 
ZH-466 (patient 
sample) 
M 43 primary 
glioblastoma 
A*03, A*33, 
B*07, B*14 
IDH1 wt 731 
(6,089) 
 
788 
 
354 
(2,692) 
 
285 
 
ZH-480 (patient 
sample) 
M 49 primary 
glioblastoma 
A*01, A*33, 
B*14, B*44 
IDH1 wt 1,220 
(7,635) 
 
7,635 
 
543 
(2,798) 
 
380 
 
ZH-483 (patient 
sample) 
M 32 primary 
glioblastoma 
A*26, A*31, 
B*44, B*51 
IDH1 R132H 749 
(3,451) 
733 
 
144 
(700) 
53 
 
ZH-511 (patient 
sample) 
F 61 primary 
glioblastoma 
A*02, A*68, 
B*39, B*49 
IDH1 wt 1,570 
(8,885) 
1,512 
 
113 
(473) 
57 
 
 
Abbreviations: HLA, Human leukocyte antigen; IDH1, isocitrate dehydrogenase 1; GSC, glioblastoma stem-like cells; PSM, peptide 
spectrum match; wt, wild type 
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